22. Standard operating procedure for personalized cancer vaccine designs

      Recent efforts to design personalized cancer immunotherapies use predicted neoantigens. To create a personalized cancer vaccine, strong-binding neoantigenic peptides are computationally predicted from matched tumor-normal sequencing data, and then ranked according to their predicted capability in stimulating a T cell response. These neoantigenic peptides arise due to various changes in the somatic genome and identification and characterization of these neoantigens is a critical step in designing these treatment regimens. This is a cross-disciplinary challenge, involving genomics, proteomics, immunology, and computational approaches.
      To read this article in full you will need to make a payment


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect